FCM
CSTL icon

Flinton Capital Management’s Castle Biosciences CSTL Stock Holding History

Flinton Capital Management’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$22K Buy
+1,232
New +$27.3K ﹤0.01% 857

Other funds holding CSTL

NAM
Nexpoint Asset Management Dallas, Texas $1.49B AUM 61.08% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Flinton Capital Management's CSTL Position: Q3 2019 in Review

Flinton Capital Management opened a new position in Castle Biosciences (CSTL) in Q3 2019: 1,232 shares worth $22K. The stake represents ﹤0.01% of the portfolio and ranks #857 among its holdings.

57 funds tracked by Wall St. Rank hold CSTL as of Q3 2019.

  • Flinton Capital Management held 1,232 shares of Castle Biosciences worth $22K as of Q3 2019.
  • Castle Biosciences was a new Flinton Capital Management position in Q3 2019.
  • Castle Biosciences made up ﹤0.01% of Flinton Capital Management's portfolio in Q3 2019, its #857 holding.
  • 57 funds tracked by Wall St. Rank held Castle Biosciences as of Q3 2019.

Based on Flinton Capital Management's 13F filing for Q3 2019, filed 14 Nov 2019.